Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
出版年份 2023 全文链接
标题
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
作者
关键词
-
出版物
Blood Advances
Volume 7, Issue 19, Pages 5898-5903
出版商
American Society of Hematology
发表日期
2023-07-19
DOI
10.1182/bloodadvances.2023010539
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma
- (2023) Edward R. Scheffer Cliff et al. JOURNAL OF CLINICAL ONCOLOGY
- Infectious complications of bispecific antibody therapy in patients with multiple myeloma
- (2023) Beatrice Z. Sim et al. Blood Cancer Journal
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- (2023) Farah Mazahreh et al. Blood Advances
- MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
- (2022) Sebastian Grosicki et al. JOURNAL OF CLINICAL ONCOLOGY
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
- (2022) Anita D'Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- Current landscape and future directions of bispecific antibodies in cancer immunotherapy
- (2022) Jing Wei et al. Frontiers in Immunology
- Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
- (2022) Guido Lancman et al. BLOOD
- Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
- (2022) Al-Ola Abdallah et al. BLOOD
- RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
- (2022) Carmelo Carlo-Stella et al. BLOOD
- Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
- (2022) Noopur Raje et al. BLOOD
- Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
- (2022) Brian Hoeynck et al. BLOOD
- Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
- (2022) Sandy W. Wong et al. BLOOD
- Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
- (2022) Naresh Bumma et al. BLOOD
- Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells
- (2022) Guido Lancman et al. BLOOD
- Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
- (2022) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
- (2021) Nizar J. Bahlis et al. JOURNAL OF CLINICAL ONCOLOGY
- Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
- (2021) Suzanne Trudel et al. BLOOD
- Risk of infections with B cell maturation antigen (BCMA) directed Immunotherapy in Multiple Myeloma
- (2021) Meera Mohan et al. Blood Advances
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now